Stay updated on Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Sign up to get notified when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.

Latest updates to the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page has been updated to reflect a new version of the study, with the addition of collaborators and a specific study identifier, while significant details about the study's objectives and inclusion/exclusion criteria have been removed.SummaryDifference19%
- Check27 days agoNo Change Detected
- Check63 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check77 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference2%
- Check85 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check99 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check106 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.3%
Stay in the know with updates to Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.